FDA approves CSL Behring rare disease treatment
March 16, 2018 at 14:34 PM EDT
The therapy was approved to treat an autoimmune disorder known as chronic inflammatory demyelinating polyneuropathy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.